Skip to content

Author

P. Achenbach

1 paper indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Oct 2026

Efficacy and safety of low-dose IL-2 in people with newly diagnosed type 1 diabetes (DIABIL-2): a double-blind, multicentre, randomised, placebo-controlled, phase 2b trial.

BACKGROUND Type 1 diabetes results from immune-mediated destruction of pancreatic β cells, driven partly by regulatory T-cell (Treg) insufficiency. We previously showed that low-dose interleukin-2 (IL-2) selectively activates Tregs in people with type 1 diabetes. We aimed to evaluate the efficacy of low-dose IL-2 in pr...

M. Rosenzwajg, A. Hartemann, M. Halbron et al. · 1 citation

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.